306 filings
Page 2 of 16
8-K
i62ccae8o0l
1 Mar 23
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
7:01am
8-K
swgxph7yh wu
22 Feb 23
Regulation FD Disclosure
5:27pm
8-K
l3mhf459qjk4oo3u3
9 Jan 23
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
7:01am
8-K
blkmi
28 Dec 22
Entry into a Material Definitive Agreement
5:00pm
8-K
mwcdk
16 Dec 22
Amicus Therapeutics Receives Positive CHMP Opinion for Pombilitiā¢ (cipaglucosidase alfa) for Late-Onset Pompe Disease
8:17am
8-K
3lxz9ckxs a4r84
16 Nov 22
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
7:01am
8-K
dnnxu9g6
7 Nov 22
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
2:31pm
8-K
odzgasbmfaupveg
7 Nov 22
Entry into a Material Definitive Agreement
7:22am
8-K
7xkr64j0wqvzul835ob
7 Nov 22
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
7:01am
8-K
76g79
28 Oct 22
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
5:18pm
8-K
9w36p ux1n8yx
14 Sep 22
Corporate Overview September 2022 At the Forefront of Therapies for Rare Diseases
7:00am
8-K
mh8hri
4 Aug 22
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
7:01am
8-K
a0h9ueopqqo2s ckn2mc
1 Aug 22
Departure of Directors or Certain Officers
5:10pm
8-K
h93gg7 rgyn5r
10 Jun 22
Departure of Directors or Certain Officers
4:05pm
8-K
xq9kl uah
10 May 22
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
4:01pm
8-K/A
mllxts28 6g3pur
9 May 22
Amicus Therapeutics Announces First Quarter 2022 Financial Results
12:54pm
8-K
1gmmcb5
9 May 22
Amicus Therapeutics Announces First Quarter 2022 Financial Results
7:00am
8-K
yws 8dirn
24 Feb 22
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
7:00am
8-K
31i ceuen9y9650
10 Jan 22
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
7:00am
8-K
9ci 296ec4
3 Dec 21
Other Events
7:00am